FNDC5/irisin improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells for myocardial infarction

BACKGROUND: The beneficial functions of bone marrow mesenchymal stem cells (BM-MSCs) decline with decreased cell survival, limiting their therapeutic efficacy for myocardial infarction (MI). Irisin, a novel myokine which is cleaved from its precursor fibronectin type III domain-containing protein 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Jingyu, Zhang, Ning, Wang, Yong, Yang, Chao, Wang, Yabin, Xin, Chao, Zhao, Jinming, Jin, Zhitao, Cao, Feng, Zhang, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288492/
https://www.ncbi.nlm.nih.gov/pubmed/32522253
http://dx.doi.org/10.1186/s13287-020-01746-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288492/
https://www.ncbi.nlm.nih.gov/pubmed/32522253
http://dx.doi.org/10.1186/s13287-020-01746-z

Ejemplares similares